Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Reply to Chanderraj et al.

Britt NS, Potter EM, Patel N, Steed ME.

Clin Infect Dis. 2017 Oct 15;65(8):1427-1428. doi: 10.1093/cid/cix553. No abstract available.

PMID:
29017243
2.

Secular Trends in Nosocomial Vancomycin-Resistant Enterococcal Bloodstream Infections Among United States Veterans Affairs Hospitals, Fiscal Years 2004 through 2014.

Britt NS, Potter EM, McKinnell JA, Patel N, Battersby SE, Steed ME.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1114-1116. doi: 10.1017/ice.2017.125. Epub 2017 Jul 11. No abstract available.

PMID:
28693646
3.

Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.

Britt NS, Potter EM, Patel N, Steed ME.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02216-16. doi: 10.1128/AAC.02216-16. Print 2017 May.

4.
5.

Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.

Britt NS, Patel N, Shireman TI, El Atrouni WI, Horvat RT, Steed ME.

J Antimicrob Chemother. 2017 Feb;72(2):535-542. doi: 10.1093/jac/dkw453. Epub 2016 Dec 20.

6.

Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.

Britt NS, Patel N, Horvat RT, Steed ME.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3070-5. doi: 10.1128/AAC.02714-15. Print 2016 May.

7.
8.

Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection.

Britt NS, Steed ME, Potter EM, Clough LA.

Infect Dis Ther. 2014 Dec;3(2):321-31. doi: 10.1007/s40121-014-0050-x. Epub 2014 Dec 3.

9.

Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity.

Steed ME, Hall AD, Salimnia H, Kaatz GW, Kaye KS, Rybak MJ.

Infect Dis Ther. 2013 Dec;2(2):187-200. doi: 10.1007/s40121-013-0021-7. Epub 2013 Nov 29.

10.

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2014 Sep;58(9):5253-61. doi: 10.1128/AAC.00098-14. Epub 2014 Jun 23.

12.

Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature.

Levy DT, Steed ME, Rybak MJ, Guo Y, Gialanella P, Hanau L, Muggia V, Ostrowsky B.

Transpl Infect Dis. 2012 Oct;14(5):E89-96. doi: 10.1111/j.1399-3062.2012.00775.x. Epub 2012 Aug 30. Review.

PMID:
22931050
14.

Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.

Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ.

Antimicrob Agents Chemother. 2012 Nov;56(11):5990-3. doi: 10.1128/AAC.01046-12. Epub 2012 Aug 6.

15.

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.

Casapao AM, Steed ME, Levine DP, Rybak MJ.

Expert Opin Pharmacother. 2012 Jun;13(8):1177-86. doi: 10.1517/14656566.2012.685718. Review.

PMID:
22594846
16.

Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):3174-80. doi: 10.1128/AAC.06439-11. Epub 2012 Apr 2.

17.

Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.

Antimicrob Agents Chemother. 2012 May;56(5):2691-5. doi: 10.1128/AAC.06185-11. Epub 2012 Feb 21.

18.

Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Rybak MJ.

Antimicrob Agents Chemother. 2012 Feb;56(2):955-9. doi: 10.1128/AAC.05849-11. Epub 2011 Nov 28.

19.

Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.

Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2011 Nov;38(5):442-6. doi: 10.1016/j.ijantimicag.2011.06.010. Epub 2011 Aug 12.

PMID:
21840181
20.

Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2011 Oct;55(10):4748-54. doi: 10.1128/AAC.00084-11. Epub 2011 Jul 25.

21.

Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.

Vidaillac C, Steed ME, Rybak MJ.

Antimicrob Agents Chemother. 2011 May;55(5):2160-5. doi: 10.1128/AAC.01291-10. Epub 2011 Feb 14.

22.

Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Steed ME, Vidaillac C, Rybak MJ.

Antimicrob Agents Chemother. 2010 Dec;54(12):5187-92. doi: 10.1128/AAC.00536-10. Epub 2010 Oct 4.

23.

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.

Steed ME, Rybak MJ.

Pharmacotherapy. 2010 Apr;30(4):375-89. doi: 10.1592/phco.30.4.375. Review.

PMID:
20334458
24.

Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes.

Kotliarov Y, Kotliarova S, Charong N, Li A, Walling J, Aquilanti E, Ahn S, Steed ME, Su Q, Center A, Zenklusen JC, Fine HA.

Cancer Res. 2009 Feb 15;69(4):1596-603. doi: 10.1158/0008-5472.CAN-08-2496. Epub 2009 Feb 3.

25.

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.

Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA.

Mol Cancer Res. 2008 Jan;6(1):21-30. doi: 10.1158/1541-7786.MCR-07-0280. Epub 2008 Jan 9.

26.

High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.

Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A, Heiss J, Rosenblum M, Mikkelsen T, Zenklusen JC, Fine HA.

Cancer Res. 2006 Oct 1;66(19):9428-36. Erratum in: Cancer Res. 2007 Mar 1;67(5):2389.

27.
28.

Benzodiazepines as a major danger in overdosage in drug abusers.

Robertson JR, Steed ME, Bucknall AB.

J R Coll Gen Pract. 1986 May;36(286):225-6. No abstract available.

29.

Trends in diploma nursing education.

Steed ME.

Can Nurse. 1968 Feb;64(2):40-1. No abstract available.

PMID:
5638284
30.

[New trends in nursing education].

Steed ME.

Infirm Can. 1968 Feb;10(2):36-7. French. No abstract available.

PMID:
5183991

Supplemental Content

Loading ...
Support Center